#USA #New York #Medtronic #Pulnovo Medical #PADN Therapy

Pulnovo Medical Secures Strategic Investment from Medtronic

Pulnovo Medical, a leader in innovative therapies targeting pulmonary hypertension and heart failure, has recently announced the successful closure of a strategic funding round totaling $100 million. This round has seen significant over-subscription and is primarily backed by Medtronic, one of the world’s largest medical technology companies. Existing investors, including EQT, Qiming Venture Partners, and Lilly Asia Ventures, along with prominent new investors such as HSG (formerly Sequoia China), have also participated in this funding, which marks a key milestone in Pulnovo's growth trajectory.

Part of this agreement includes a commercial partnership between Pulnovo and Medtronic, aimed at optimizing market opportunities by leveraging Medtronic’s extensive market access capabilities.

Innovative Solutions for Complex Health Issues

Pulnovo’s exclusive PADN (Pulmonary Artery Denervation) system addresses a critical mechanism underlying cardiopulmonary disease. Clinical studies have demonstrated significant benefits, including improved functional capacity for patients. To date, the company has conducted 1,500 PADN procedures globally and received regulatory approvals in seven countries. Their expansion efforts are underway in the European Union, the Middle East, and China. In the United States, Pulnovo has also been granted FDA breakthrough device designation and is actively running IDE clinical trials.

Cynthia Chen, Chair and President of Pulnovo Medical, emphasized that the integration of long-term capital and expertise will aid the company in transitioning to a fully integrated global platform. Chen reiterated their commitment to driving meaningful innovations that significantly impact patient outcomes around the globe.

Strategic Global Partnership and Growth

The newly acquired funding is set to bolster Pulnovo’s strategic collaboration with global industry and financial partners, enhancing their capabilities in clinical development and regulatory strategy while supporting international market expansion. Proceeds will support ongoing clinical development, global regulatory submissions, and investments in their core technological platform.

With this expansion of leadership, Andre Xiao has joined the team as Chief Strategy Officer, focusing on securing vital financing and strategies on a global scale. His vast experience in health sector investments from prominent firms like Citadel and Millennium Management will further strengthen Pulnovo's connections in the global financial markets.

The Science Behind PADN Therapy

Pulnovo’s PADN system represents a trailblazing mini-invasive therapy that modulates the overly activated sympathetic nerve activity contributing to pulmonary vascular remodeling and disease progression. Targeted at fundamental disease mechanisms, PADN has shown clinically meaningful results in global studies, including enhancing patient functional capacity and reducing major adverse clinical events.

The therapy has received recognition in various international clinical guidelines and is referenced in the European Society of Cardiology’s and European Respiratory Society’s guidelines for pulmonary hypertension management dating back to 2022. Ongoing clinical trials across Europe, Asia, and the newly launched IDE PULSE-LHD study in the U.S. aim to build robust evidence for PADN, addressing unmet medical needs in heart failure patients.

About Pulnovo Medical

Pulnovo Medical is an innovative medical technology company focused on advancing interventional therapies for pulmonary hypertension and heart failure. Dedicated to creating clinical value, Pulnovo develops cutting-edge solutions on its proprietary platform while emphasizing global clinical development and market readiness to improve patient outcomes worldwide.